بدائل البحث:
significant cause » significant change (توسيع البحث), significant changes (توسيع البحث), significant gap (توسيع البحث)
cause decrease » caused decreased (توسيع البحث), use decreased (توسيع البحث), causes increased (توسيع البحث)
small decrease » small increased (توسيع البحث)
point decrease » point increase (توسيع البحث)
significant cause » significant change (توسيع البحث), significant changes (توسيع البحث), significant gap (توسيع البحث)
cause decrease » caused decreased (توسيع البحث), use decreased (توسيع البحث), causes increased (توسيع البحث)
small decrease » small increased (توسيع البحث)
point decrease » point increase (توسيع البحث)
-
261
-
262
-
263
-
264
Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.
منشور في 2024"…<p>Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…"
-
265
Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.
منشور في 2024"…<p>Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…"
-
266
-
267
-
268
-
269
-
270
-
271
-
272
Summary of post-treatment disease course measures from MDMA-AT publications.
منشور في 2025الموضوعات: -
273
-
274
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
منشور في 2025الموضوعات: -
275
-
276
-
277
-
278
Summary of post-treatment disease course measures from off-label medications clinical trials.
منشور في 2025الموضوعات: -
279
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
280
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
منشور في 2025الموضوعات: